




SUPPLEMENTARY FIGURES



**Figure S1.** Penetration Aspiration Scale (PAS) score frequency between viscosities and patients. PAS 1–2 indicates safe swallow and PAS 3–8, unsafe swallow; HNC, head and neck cancer.



**Figure S2.** Effect of saliva (samples with saliva) on viscosity measured with a rotational viscometer within groups.



**Figure S3.** Palatability of the study product presented for all patients valuated with a visual analogue scale (0–10).

SUPPLEMENTARY TABLES

**Table S1.** Comparison between viscosities of oral residue among the study groups. *HNC: Head and neck cancer.*

<b>OLDER</b>	<b>&lt;50mPa·s (n=36)</b>	<b>250mPa·s (n=32)</b>	<b>1000mPa·s (n=36)</b>	<b>2000mPa·s (n=36)</b>
<b>Oral residue</b>	63.89% (23)	90.63% (29)	86.11% (31)	72.22% (26)
<50mPa·s		0.008	0.013	0.752
250mPa·s			1.000	0.023
1000mPa·s				0.041
<b>HNC</b>	<b>&lt;50mPa·s (n=31)</b>	<b>250mPa·s (n=25)</b>	<b>1000mPa·s (n=27)</b>	<b>2000mPa·s (n=31)</b>
<b>Oral residue</b>	45.16% (14)	64.00% (16)	66.67% (18)	64.52% (20)
Liquid		0.041	0.046	0.114
Nectar			0.683	0.617
Honey				0.683
Pudding				
<b>PARKINSON</b>	<b>&lt;50mPa·s (n=30)</b>	<b>250mPa·s (n=29)</b>	<b>1000mPa·s (n=30)</b>	<b>2000mPa·s (n=30)</b>
<b>Oral residue</b>	33.33% (10)	62.07% (18)	56.67% (17)	53.33% (16)
<50mPa·s		0.027	0.070	0.077
250mPa·s			1.000	0.683
1000mPa·s				1.000
<b>STROKE</b>	<b>&lt;50mPa·s (n=30)</b>	<b>250mPa·s (n=28)</b>	<b>1000mPa·s (n=30)</b>	<b>2000mPa·s (n=31)</b>
<b>Oral residue</b>	30.00% (9)	46.46% (13)	50.00% (15)	54.84% (17)
<50mPa·s		0.131	0.073	0.023
250mPa·s			0.683	0.683
1000mPa·s				0.617

**Table S2.** Comparison between viscosities of pharyngeal residue among the study groups. *HNC: Head and neck cancer.*

<b>OLDER</b>	<b>&lt;50mPa·s (n=36)</b>	<b>250mPa·s (n=32)</b>	<b>1000mPa·s (n=36)</b>	<b>2000mPa·s (n=36)</b>
<b>Pharyngeal residue</b>	50.00% (18)	59.38% (19)	52.78% (19)	55.56% (20)
<50mPa·s		0.450	1.000	0.724
250mPa·s			0.683	1.000
1000mPa·s				1.000
<b>HNC</b>	<b>&lt;50mPa·s (n=31)</b>	<b>250mPa·s (n=25)</b>	<b>1000mPa·s (n=27)</b>	<b>2000mPa·s (n=31)</b>
<b>Pharyngeal residue</b>	87.10% (27)	92.00% (23)	88.89% (24)	93.55% (29)
<50mPa·s		0.475	1.000	0.480
250mPa·s			1.000	0.480
1000mPa·s				1.000
<b>PARKINSON</b>	<b>&lt;50mPa·s (n=30)</b>	<b>250mPa·s (n=29)</b>	<b>1000mPa·s (n=30)</b>	<b>2000mPa·s (n=30)</b>
<b>Pharyngeal residue</b>	60.00% (18)	72.41% (21)	73.33% (22)	76.67% (23)
<50mPa·s		0.371	0.221	0.074
250mPa·s			1.000	1.000
1000mPa·s				1.000
<b>STROKE</b>	<b>&lt;50mPa·s (n=30)</b>	<b>250mPa·s (n=28)</b>	<b>1000mPa·s (n=30)</b>	<b>2000mPa·s (n=31)</b>
<b>Pharyngeal residue</b>	43.33% (13)	60.71% (17)	66.67% (20)	61.29% (19)
<50mPa·s		0.450	0.077	0.182
250mPa·s			0.371	1.000
1000mPa·s				1.000